Results 271 to 280 of about 776,039 (330)

Evaluating the use of diagnostic CT with flattening filter free beams for palliative radiotherapy: Dosimetric impact of scanner calibration variability

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose Palliative radiotherapy comprises a significant portion of the radiation treatment workload. Volumetric‐modulated arc therapy (VMAT) improves dose conformity and, in conjunction with flattening filter free (FFF) delivery, can decrease treatment times, both of which are desirable in a population with a high probability of retreatment ...
Madeleine L. Van de Kleut, Lesley A. Buckley, Elsayed S. M. Ali   +2 more
wiley   +1 more source

Commissioning of Halcyon enhanced leaf model in the Eclipse treatment planning system: Focus on simple slit fields and VMAT dose calculation

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose The dual‐layer multileaf collimator (MLC) in Halcyon adds complexities to the dose calculation process owing to the variability of dosimetric characteristics with leaf motion. Recently, an enhanced leaf model (ELM) was developed to refine the MLC model in the Eclipse treatment planning system. This study investigates the performance of
Ryohei Miyasaka, Mari Shirai, Mitsunobu Igari, Yume Kojima, Yuki Kozawa, Toru Kawachi, Ryusuke Hara   +6 more
wiley   +1 more source

Closing the gap in plan quality: Leveraging deep‐learning dose prediction for adaptive radiotherapy

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose Balancing quality and efficiency has been a challenge for online adaptive therapy. Most systems start the online re‐optimization with the original planning goals. While some systems allow planners to modify the planning goals, achieving a high‐quality plan within time constraints remains a common barrier.
Sean J. Domal, Austen Maniscalco, Justin Visak, Michael Dohopolski, Dominic Moon, Vladimir Avkshtol, Dan Nguyen, Steve Jiang, David Sher, Mu‐ Han Lin   +9 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Drug Approval and Drug Effectiveness

Annual Review of Clinical Psychology, 2014
Data on the efficacy and safety of psychiatric medicines should form the foundation of evidence-based treatment practices. The US Food and Drug Administration (FDA) reviews such data in determining whether to approve new treatments, and the published literature serves as a repository for evidence on treatment benefits and harms.
Glen I. Spielmans, Irving Kirsch
openaire   +3 more sources

Polypharmacology of Approved Anticancer Drugs

Current Drug Targets, 2017
The major drug discovery efforts in oncology have been concentrated on the development of selective molecules that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets. However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents ...
Amelio, Ivano, Lisitsa, Andrey, Knight, Richard A., Melino, Gennaro, Antonov, Alexey V.   +4 more
openaire   +5 more sources

Drug Approval Highlights for 2003

The Nurse Practitioner, 2004
In the past 12 months, the FDA has approved important new pharmaceutical drugs and devices of particular interest to primary health care providers. The drugs include: Oxytrol (for urinary incontinence), Valtrex (for reducing the risk of heterosexual transmission of genital herpes), Femring (for vaginal delivery of hormone therapy), Uroxatral (for ...
Laustsen, Gary, Wimett, Lynn
openaire   +3 more sources

Drug Approval and Surveillance

International Journal of Gynecology & Obstetrics, 1980
ABSTRACTThe author proposes that current regulations governing the licensing of drugs, particularly in the United States, need to be changed and replaced by a system of provisional or conditional licensing and increased postmarketing surveillance of drug use.
openaire   +3 more sources

Approving new drugs

Science, 2017
As the Trump administration takes shape, there is much speculation as to what major changes will be made. A dominant theme of the Trump campaign was to cut through bureaucracy in Washington, D.C., thereby enhancing innovation and bringing new technology to Americans more quickly.
openaire   +3 more sources

2017 FDA drug approvals

Nature Reviews Drug Discovery, 2018
This corrects the article DOI: 10.1038/nrd.2018.4.
openaire   +4 more sources